The BTF welcomes the provisional findings of the Competition and Markets Authority (CMA) which has found that Concordia overcharged the NHS by millions for the supply of Liothyronine. There are many thyroid patients who have told us that this medicine makes a huge difference to their lives and the enormous price rise has caused significant confusion and distress. We look forward to the CMA's final decision and very much hope it will take account of patients’ clinical needs and lead to an improvement in care.